• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三种不同方式施测短式 6 维度版本 2 的一致性。

Consistency Between Three Different Ways of Administering the Short Form 6 Dimension Version 2.

机构信息

Unité d'Évaluation des Technologies et des Modes d'Intervention en Santé and Centre de Recherche du Centre hospitalier universitaire de Sherbrooke, Centre Intégré Universitaire de Santé et Services Sociaux de l'Estrie-CHUS, Sherbrooke, QC, Canada.

Department of Economics, University of Sherbrooke, Sherbrooke, QC, Canada.

出版信息

Value Health. 2019 Jul;22(7):837-842. doi: 10.1016/j.jval.2018.12.012. Epub 2019 May 17.

DOI:10.1016/j.jval.2018.12.012
PMID:31277832
Abstract

BACKGROUND

The Short Form 6 Dimension (SF-6D) is a multi-attribute utility instrument derived from the Short-Form 36 Health Survey Version 2 (SF-36v2) quality of life questionnaire and is used to calculate quality-adjusted life years (QALYs) on a scale 0 to 1. The SF-6Dv2 is a new version of the SF-6D.

OBJECTIVE

The aim of this study was to assess the consistency of respondents' answers to 3 different methods to administer this new version.

METHODS

SF-6Dv2 utility values were generated from the SF-36v2 using the following: (1) full questionnaire with 36 items (SF-6Dv2); (2) subset questionnaire with 10 items (SF-6Dv2); (3) SF-6Dv2 administered as an independent instrument (rephrased questionnaire with only 6 items [SF-6Dv2]). The order of the 3 instruments was randomly allocated between respondents.

RESULTS

A total of 782 respondents from Quebec, Canada, were interviewed, out of whom 697 fully completed the survey. Very few deviations in respondents' answers were observed between the 3 instruments, with mean weighted kappa of 0.79 (range 0.61-0.91) and mean global consistency index of 70% (range 54-83). Maximal difference in utility values generated was found between SF-6Dv2 and SF-6Dv2 (mean difference 0.016, P < .01), whereas minimal difference was found between SF-6Dv2 and SF-6Dv2 (0.002, P = .38). No ceiling effect was observed.

CONCLUSIONS

The SF-6Dv2 was designed to derive utilities from the SF-36v2, and our results indicate that it is still preferable to use the full questionnaire, although the difference with other variants of the questionnaire is very small. To use the SF-6Dv2 as an independent instrument will thus introduce minimal bias in utility values generated.

摘要

背景

简短表格 6 维度(SF-6D)是一种源自简短表格 36 健康调查版本 2(SF-36v2)的多维效用工具,用于在 0 到 1 的范围内计算质量调整生命年(QALYs)。SF-6Dv2 是 SF-6D 的新版本。

目的

本研究旨在评估受访者对 3 种不同管理新版本方法的答案的一致性。

方法

使用以下方法从 SF-36v2 生成 SF-6Dv2 效用值:(1)包含 36 个项目的完整问卷(SF-6Dv2);(2)包含 10 个项目的子问卷(SF-6Dv2);(3)作为独立工具管理的 SF-6Dv2(重新表述的只有 6 个项目的问卷[SF-6Dv2])。受访者之间随机分配 3 种仪器的顺序。

结果

从加拿大魁北克省共采访了 782 名受访者,其中 697 名受访者完整完成了调查。在 3 种仪器之间,受访者的答案几乎没有偏差,加权平均 kapp 值为 0.79(范围为 0.61-0.91),平均总体一致性指数为 70%(范围为 54-83)。在效用值生成中发现 SF-6Dv2 和 SF-6Dv2 之间的最大差异(平均差异 0.016,P<.01),而 SF-6Dv2 和 SF-6Dv2 之间的最小差异(0.002,P=.38)。未观察到上限效应。

结论

SF-6Dv2 旨在从 SF-36v2 中推导出效用,我们的结果表明,尽管与问卷的其他变体差异很小,但最好还是使用完整的问卷。因此,使用 SF-6Dv2 作为独立工具将在生成的效用值中引入最小的偏差。

相似文献

1
Consistency Between Three Different Ways of Administering the Short Form 6 Dimension Version 2.三种不同方式施测短式 6 维度版本 2 的一致性。
Value Health. 2019 Jul;22(7):837-842. doi: 10.1016/j.jval.2018.12.012. Epub 2019 May 17.
2
Exploring the consistency of the SF-6Dv2 in a breast cancer population.探索SF-6Dv2在乳腺癌人群中的一致性。
Expert Rev Pharmacoecon Outcomes Res. 2021 Oct;21(5):1017-1024. doi: 10.1080/14737167.2021.1842734. Epub 2020 Dec 1.
3
Quebec Health-related Quality of Life Population Norms in Adults Using the SF-6Dv2: Decomposition by Sociodemographic Data and Health Problems.魁北克省使用SF-6Dv2的成年人健康相关生活质量人群规范:按社会人口数据和健康问题进行分解
Med Care. 2022 Jul 1;60(7):545-554. doi: 10.1097/MLR.0000000000001730. Epub 2022 Apr 26.
4
Developing a New Version of the SF-6D Health State Classification System From the SF-36v2: SF-6Dv2.从 SF-36v2 开发 SF-6D 健康状态分类系统新版本:SF-6Dv2。
Med Care. 2020 Jun;58(6):557-565. doi: 10.1097/MLR.0000000000001325.
5
Exploring the consistency of the SF-6D.探索 SF-6D 的一致性。
Value Health. 2013 Sep-Oct;16(6):1023-31. doi: 10.1016/j.jval.2013.06.018.
6
Psychometric properties of the SF-6Dv2 in an Iranian breast cancer population.SF-6Dv2 在伊朗乳腺癌人群中的心理测量特性。
Breast Cancer. 2021 Jul;28(4):937-943. doi: 10.1007/s12282-021-01230-3. Epub 2021 Mar 5.
7
Mapping the cancer-specific FACT-B onto the generic SF-6Dv2.将癌症特异性 FACT-B 映射到通用 SF-6Dv2 上。
Breast Cancer. 2021 Jan;28(1):130-136. doi: 10.1007/s12282-020-01141-9. Epub 2020 Jul 25.
8
Cancer population norms using a new value set for the SF-6Dv2 based on the preferences of patients with breast or colorectal cancer in Quebec.使用基于魁北克乳腺癌或结直肠癌患者偏好的 SF-6Dv2 新效价集的癌症人群规范。
Qual Life Res. 2024 Jun;33(6):1605-1619. doi: 10.1007/s11136-024-03653-9. Epub 2024 Apr 20.
9
A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population.SF-6Dv2 与 SF-6D UK 效用值在混合患者和健康人群中的比较。
Pharmacoeconomics. 2021 Aug;39(8):929-940. doi: 10.1007/s40273-021-01033-6. Epub 2021 May 27.
10
Valuing the SF-6Dv2 Classification System in the United Kingdom Using a Discrete-choice Experiment With Duration.采用具有持续时间的离散选择实验评估英国的 SF-6Dv2 分类系统
Med Care. 2020 Jun;58(6):566-573. doi: 10.1097/MLR.0000000000001324.

引用本文的文献

1
Using patient-reported outcome measures in clinical trials: perspectives for and against a modular approach.在临床试验中使用患者报告的结局指标:支持和反对模块化方法的观点。
Med J Aust. 2025 Apr 21;222(7):327-330. doi: 10.5694/mja2.52629. Epub 2025 Mar 11.
2
Health utility scores of six common cancers in China measured by SF-6Dv2.采用SF-6Dv2量表测量的中国六种常见癌症的健康效用得分。
Health Qual Life Outcomes. 2025 Jan 12;23(1):5. doi: 10.1186/s12955-025-02332-8.
3
Quality-Adjusted Life Expectancy Norms Based on the EQ-5D-5L and SF-6Dv2 for China.
基于EQ-5D-5L和SF-6Dv2的中国质量调整生命预期规范
Appl Health Econ Health Policy. 2025 Mar;23(2):291-310. doi: 10.1007/s40258-024-00925-w. Epub 2024 Dec 13.
4
The Short Form 6 Dimensions (SF-6D): Development and Evolution.简短健康调查问卷6维度量表(SF-6D):发展与演变
Appl Health Econ Health Policy. 2025 Jan;23(1):19-33. doi: 10.1007/s40258-024-00919-8. Epub 2024 Oct 26.
5
Assessing health-related quality of life of Chinese population using CQ-11D.使用 CQ-11D 评估中国人群的健康相关生命质量。
Health Qual Life Outcomes. 2024 Apr 19;22(1):34. doi: 10.1186/s12955-024-02250-1.
6
Psychometric performance of EQ-5D-5L and SF-6DV2 in measuring health status of populations in Chinese university staff and students.EQ-5D-5L 和 SF-6Dv2 在测量中国高校教职工和学生人群健康状况的心理计量学性能。
BMC Public Health. 2023 Nov 22;23(1):2314. doi: 10.1186/s12889-023-17208-z.
7
Comparative performance and mapping algorithms between EQ-5D-5L and SF-6Dv2 among the Chinese general population.中国一般人群中 EQ-5D-5L 与 SF-6Dv2 之间的比较性能和映射算法。
Eur J Health Econ. 2024 Feb;25(1):7-19. doi: 10.1007/s10198-023-01566-x. Epub 2023 Jan 29.
8
Impact of Immediate and Delayed Breast Reconstruction on Quality of Life of Breast Cancer Patients.即刻与延迟乳房重建对乳腺癌患者生活质量的影响。
Int J Environ Res Public Health. 2022 Jul 13;19(14):8546. doi: 10.3390/ijerph19148546.
9
Mapping the Minnesota Living with Heart Failure Questionnaire (MLHFQ) to SF-6Dv2 in Chinese patients with heart failure.将明尼苏达州心力衰竭生活质量问卷(MLHFQ)映射到中国心力衰竭患者的 SF-6Dv2 中。
Health Qual Life Outcomes. 2022 Jun 20;20(1):98. doi: 10.1186/s12955-022-02004-x.
10
Comparison of the measurement properties of SF-6Dv2 and EQ-5D-5L in a Chinese population health survey.SF-6Dv2 和 EQ-5D-5L 在中国人群健康调查中的测量性能比较。
Health Qual Life Outcomes. 2022 Jun 16;20(1):96. doi: 10.1186/s12955-022-02003-y.